Conflict of interest statement:
BAW receives research funding from Novartis. CFD is the Chief
Adjudicator for the Stryker EVOLVE Flow Diverter clinical trial. KAS
receives research funding from Novartis, Pfizer, Daiichi-Sankyo, Sanofi,
and Dova. EM is a consultant for Novartis. IF is a consultant for
NobelPharma, Novartis, and Apogee Pharmaceuticals and is the Chair of
the Data Safety Monitoring Board for Pfizer. All authors declare no
commercial or financial relationships that could be construed as a
potential conflict of interest.